Plastics Pipe, Pipe Fitting, and Unlaminated Profile Shape Manufacturing (U.S.) — NAICS 32612

An investor's primer. NAICS = North American Industry Classification System, the U.S. government's standard for grouping businesses. This is a "rollup" of two child industries; its value is the contrast between them.

1. Overview

This industry converts plastic resin into long, continuous shapes by pushing it through a die (extrusion) or forming it in a mold. It splits into two halves that behave almost nothing alike:

• Rigid pipe and fittings (NAICS 326122) — the water main under the street, the sewer, the drain stack in a house, the electrical and fiber conduit in the ground. Steady, replacement-driven, infrastructure-levered.
• Non-rigid profile shapes (NAICS 326121) — flexible tubing, rod and machinable stock, sausage casings, and, at the high end, precision medical tubing for catheters and IV (intravenous) lines. A commodity base with a fast-growing, high-margin medical tip.

Together they are a genuine mid-size manufacturing sector: about $27.2 billion of shipments, 822 plants, and 44,000 workers [1]. But the two halves differ on almost every axis an investor cares about — size, growth direction, who owns the companies, how you'd buy in, and which regulators keep the owners awake at night. The pipe half is roughly two-thirds of the level and the more investable; the profile half is one-third and holds the single most valuable niche (medical tubing) — reachable almost entirely through private markets. This primer leads with that contrast, then covers the level as a whole.

2. What's inside — the two child industries and how they differ

The level contains exactly two NAICS industries. They share a factory and a resin bill; they share little else.

PVC = polyvinyl chloride; HDPE = high-density polyethylene; DWV = drain-waste-vent; HHI = Herfindahl-Hirschman Index (a concentration gauge, defined in Section 3); DOJ = U.S. Department of Justice; FDA = Food and Drug Administration; PFAS = per- and polyfluoroalkyl substances. The remaining acronyms are defined where they first do work below.

The one-line takeaway: the pipe half is a bulky, freight-bound, infrastructure-cycle building-materials business; the profile half is a lighter, ship-anywhere business whose returns are decided by how far an owner has moved its mix from commodity trim toward regulated, cleanroom-grade medical tubing. Same NAICS parent, two different investment cases.

3. How big it is

Federal figures for the whole level (NAICS 32612), drawn from our ground-truth stats [1]:

Two vintages are mixed here: shipments and concentration are 2022 (Economic Census), while plant, employment, and payroll counts are 2023 (County Business Patterns). The children reconcile cleanly into the parent — establishments (335 + 487), employment (18,949 + 25,348), and payroll ($1.25B + $1.66B) each sum exactly to the level, and the two shipment figures ($9.0B + $18.2B) sum to it within rounding [1].

Concentration is low and, notably, lower than either child. At the level, the four largest firms hold 27.8% of shipments, the top 8 hold 40.8%, the top 20 hold 59.9%, and the top 50 hold 78%; the HHI is 290.7 [1]. (HHI sums the squared market shares of all firms; U.S. antitrust convention treats anything below 1,500 as "unconcentrated.") The rollup CR4 (27.8%) sits below both children's top-4 shares (pipe ~33% [2], profile ~41% [3]) — because the leaders in one niche do not compete in the other, so combining the two codes dilutes measured concentration. Read the low national HHI with care: freight economics make the pipe market far more concentrated inside any given metro, and certification-gated niches (large-diameter water main, medical tubing) each have only a handful of credible players.

Undercount caveat — modest and definitional, not demographic. This is capital-intensive factory work — real plants employing dozens each, not government agencies or tiny sole proprietors — so the federal statistics count it well; small/individual ownership does not dominate, so the usual "self-employed undercount" barely applies. The genuine caveats are three: (1) the rigid vinyl window, door, and siding "profiles" most people picture are not in 326121 — they sit in other codes — so this level is narrower than the everyday phrase "plastic profiles" [3]; (2) a great deal of tube and pipe extrusion is done in-house by medical-device and construction firms and counted under their primary codes; and (3) the Census counts domestic production only, and the U.S. is a net importer of plastic pipe (private trade data put imports near $1.4 billion) [2], so national consumption runs somewhat above the $27.2 billion of domestic shipments.

4. The investable universe — where value concentrates across the children

The two halves offer completely different menus.

Pipe (326122) — the public-market half. There is one large U.S.-listed pure-play and a set of segment exposures [2]:

The largest producer in the country, JM Eagle, is private (Wang family), as are Aliaxis/IPEX, Performance Pipe (Chevron Phillips Chemical), Charlotte Pipe, Diamond Plastics, and National Pipe [15][16]. Water-infrastructure exposure without single-plant risk is available through the big distributors Core & Main (CNM) and Ferguson (FERG).

Profile (326121) — the private-market half. There is no U.S.-listed pure-play [3]. Public exposure is only ever a thin slice of a diversified or foreign-listed group — Saint-Gobain (Euronext Paris: SGO) and Trelleborg (Nasdaq Stockholm: TREL) in medical/sealing tubing, Nordson (Nasdaq: NDSN) in catheter components, Viscofan (Madrid: VIS) in sausage casings [4][17]. The economic center of gravity is private-equity-owned: the flagship is Zeus, a fluoropolymer medical-tubing specialist bought by buyout firm EQT in 2024 at roughly $3.4 billion (about 17x revenue on ~$200M sales) — a multiple only a regulated, high-barrier product mix commands [18][19]. Tekni-Plex (Genstar) and Pexco (Odyssey) are serial roll-ups of custom extruders [20][21].

Where the value sits: the pipe half is where public investors can actually own the theme cleanly; the profile half is where the single richest niche (medical tubing) lives, but it trades privately. For investors reaching for "plastic profile" exposure, note that the listed rigid-vinyl building-products names (e.g. Quanex, NYSE: NX, which reported $1.84B FY2025 sales after acquiring Tyman) are a different NAICS code and a different demand cycle [22].

5. How the money works

Both halves run the same core equation — the spread between resin cost and selling price, multiplied by volume, over a fixed factory base — but pull different levers on top of it.

• Resin is the swing factor for both. Plastic resin (PVC, polyethylene, polypropylene, and pricier engineering/fluoropolymers) is the majority of cost of goods, so gross margin is really a resin-to-price spread. When resin falls faster than selling prices, margins expand; a lag on the way up squeezes them. Resin sat in a soft, buyer's-market range through 2025, with Westlake announcing a PVC plant shutdown in December 2025 to tighten supply [23][24]. Producers pass moves through via indexed contracts and surcharges; some (Westlake, Performance Pipe) make their own resin and partly hedge the spread [13]. Otter Tail reported average pipe prices declined 15% in 2025 while material-input costs declined 14% [14].
• Utilization. Extrusion and molding lines are fixed-cost assets that reward running near 24/7; idle line time from a construction slowdown is lost margin on both sides.
• Pipe-specific: freight defines the map. Pipe is bulky and cheap per pound, so it is uneconomic to ship far. Otter Tail states that shipping costs are generally prohibitive to competing nationally in PVC pipe [14]. That makes the pipe business regional — plants serve a delivery radius, local markets are more concentrated than national shares suggest, and a dense plant footprint is a moat [2].
• Profile-specific: mix is the ceiling. Commodity flexible trim earns thin margins; tight-tolerance, cleanroom-made medical tubing earns far more because few shops can pass the qualification. Value-added secondary work (printing, tipping, coiling, cleanroom packaging) turns a commodity extrusion into a device-ready component [3]. The whole private-equity playbook on this side is mix shift from commodity toward medical.
• Shared moat: tooling and certification. Custom dies, once qualified to a customer's part, make switching suppliers costly; on the medical and drinking-water ends, certification cycles lock relationships in for years.
• Customer concentration. Both halves face it: Otter Tail reported two national distributors accounted for 47% of Plastics-segment revenue in 2025; ADS reported its ten largest customers represented approximately 50% of FY2026 sales [14][10].

Recent profitability is not normal. Public-company margins require caution. ADS produced a 38.3% consolidated gross margin, 20.3% operating margin, and 31.6% adjusted EBITDA margin in FY2026 — but those results include higher-value chambers, fittings, tanks, and treatment products [10]. Otter Tail's PVC pipe segment reported extraordinary economics that management explicitly says should not be capitalized as normal: pipe prices rose sharply in 2021, peaked in 2022, and remain above historical levels, with earnings expected to normalize further [14].

6. What drives demand

The two halves ride partly overlapping, partly separate engines:

• Building and construction (both). Roughly half of pipe demand and much of the flexible-profile/trim volume track housing starts and remodeling — the cyclical, interest-rate-sensitive part of the level [2][3]. Census reported May 2026 U.S. housing starts at a seasonally adjusted annual rate of 1.177 million, 8.7% below May 2025, demonstrating the cyclical pressure [25].
• Municipal water and sewer (pipe). The durable structural driver: plastic keeps taking share from corroding iron, steel, concrete, and clay because it is lighter, installs faster, and lasts longer at lower installed cost [2]. The EPA's 7th Drinking Water Infrastructure Needs Survey identifies $625 billion of need over 20 years, including $422.9 billion for distribution and transmission; the 2022 Clean Watersheds Needs Survey reports $630.1 billion of 20-year need [26][27]. Caveat: these are total infrastructure-needs estimates spanning labor, treatment, storage, engineering, and competing materials — they cannot be translated dollar-for-dollar into plastic-pipe revenue.
• Lead-pipe replacement (pipe). The EPA's 2024 Lead and Copper Rule Improvements (LCRI) require water systems to replace essentially all lead service lines, most within ten years (by ~2037), funded partly by the 2021 Infrastructure Investment and Jobs Act (IIJA), which earmarked $15 billion for lead-line replacement plus $11.7 billion in flexible Drinking Water State Revolving Fund money [5]. Much replacement pipe is plastic.
• Medical devices (profile). Aging populations and the shift to minimally invasive procedures drive catheter and tubing volume; the fluoropolymer tubing market alone was estimated at about $622 million in 2025, projected to grow to ~$813 million by 2030 (~5.5% a year), with broader medical tubing and micro-extrusion growing faster still [4]. Largely non-cyclical.
• Electrical, telecom, and data-center conduit (pipe) and automotive/industrial seals and food casings (profile) round out the mix — the casings piece is steady, defensive demand [17].
• Reshoring of medical-supply-chain manufacturing is a forward tailwind for domestic precision extruders [4].

7. Regulation

Two very different regimes sit under one code, joined by a common chemical thread.

Pipe — product standards plus a policy tailwind. Pipe touching drinking water must meet NSF/ANSI/CAN 61 (health-effects testing) and be certified to NSF/ANSI 14, now required by every major model plumbing code; pressure and dimensional standards come from ASTM International and the American Water Works Association [28]. Certification is a real barrier to entry and a friction on imports. On the demand side, the LCRI and IIJA funding — plus "Build America, Buy America" content rules — act as tailwinds; Build America, Buy America explicitly includes plastic and polymer-based products, including PVC, as construction materials, which can favor domestic plants on federally assisted projects [5][29].

Profile — medical rules as a moat, chemistry as a risk. Medical tubing must meet FDA requirements, USP (U.S. Pharmacopeia) Class VI biocompatibility, and ISO 13485 quality systems, produced in cleanrooms — the barrier behind medical-grade margins [3]. Food-grade casings fall under FDA food-contact and USDA oversight.

The shared overhang is chemical. The EPA (Environmental Protection Agency) designated vinyl chloride — the feedstock for all PVC — a High-Priority Substance for risk evaluation under the Toxic Substances Control Act (TSCA) in December 2024, publishing a draft scope in January 2025 [7]. Separately, EPA is running risk evaluations of phthalate plasticizers (DEHP and others) that make flexible PVC soft; a DEHP evaluation was released in December 2025, and EPA has preliminarily found unreasonable worker risk for a related phthalate [8]. On the profile side, PFAS scrutiny reaches directly into the highest-margin fluoropolymer medical tubing (PTFE, FEP, PFA) [4]. Because PVC underpins the bulk of the pipe half and the commodity part of the profile half, and fluoropolymers underpin the profile crown jewel, these reviews touch the most important material families in the whole level.

Pipe-specific legal overhang: since August 2024 the DOJ Antitrust Division has run a grand-jury probe, and civil class actions allege PVC pipe makers used the industry price index (published by the Oil Price Information Service, OPIS) to coordinate prices from about 2021 — named defendants span most of the pipe industry; OPIS settled for $3 million and agreed to cooperate [6]. Westlake recorded a $67 million first-quarter 2026 charge to settle direct-purchaser PVC pipe-and-fittings litigation [30].

8. Consolidation

Both halves are fragmented in the middle and concentrated in niches, and both are actively consolidating — but the buyers and logic differ.

• Pipe consolidation is strategic and resin-integrated: Westlake built its PVC-pipe position through acquisitions and is adding molecular-oriented PVC (PVCO) capacity; Aliaxis has bought its way into North America (Valencia Pipe, ~$250M; Johnson Controls' CPVC sprinkler business); Advanced Drainage Systems expanded via septic and recycling deals; Georg Fischer acquired Uponor in 2023, expanding its North American plastic piping presence [13][31][10][32]. Freight-defined regional markets make well-located independent plants attractive tuck-ins.
• Profile consolidation is private-equity-led roll-ups: buyers acquire custom or medical extruders, professionalize operations, bolt on smaller shops, and re-rate the mix toward medical — Pexco (Odyssey), Tekni-Plex (Genstar), and the premium paid for Zeus (EQT) are the template [18][20][21].

The analytical caution from Section 3 holds: the level's low national HHI (290.7) understates real-world concentration, because freight (pipe) and certification (both) carve the market into local and niche segments where only a few players compete.

9. Risks

• Resin-price and margin volatility — the core spread can compress fast, and inventory gains/losses amplify quarter-to-quarter noise, on both halves [23].
• Construction and rate cyclicality — with roughly half of demand tied to building, a housing downturn cuts pipe volumes and commodity-profile trim alike [2][3].
• Chemical and environmental regulation — vinyl chloride and phthalate TSCA reviews threaten flexible PVC (both halves), and PFAS restrictions threaten fluoropolymer medical tubing (the profile crown jewel) [7][8][4].
• Pipe-specific antitrust — the DOJ probe and PVC price-fixing class actions carry potential damages, and the risk that the 2021–2023 pricing behavior that inflated margins does not repeat [6][30].
• Import competition — as a net importer of pipe, the U.S. faces lower-cost commodity product from Canada, Mexico, and Asia, capping pricing power on undifferentiated grades [2].
• Customer concentration — both halves face it: pipe distributors and medical device OEMs can each dominate a supplier's revenue [14][10][3].
• No clean public pure-play for the profile half — public investors cannot cleanly own the best part of the level.

10. How to invest and the outlook

The pipe half is the public-market route. Advanced Drainage Systems (WMS) is the cleanest listed pure-play; Atkore (ATKR), Westlake (WLK), and Otter Tail (OTTR) offer segment exposure inside larger businesses; Core & Main (CNM) and Ferguson (FERG) give diversified water-infrastructure exposure through distribution [9][11][12][14]. Each carries its own baggage — Atkore and Westlake sit under the PVC antitrust cloud (Westlake has already settled for $67M); Otter Tail's pipe earnings have been abnormally high and may normalize [6][30][14].

The profile half is the private-market route. With no U.S. pure-play, access is through private equity (custom and medical extruder roll-ups), direct ownership of regional shops, or the diluted foreign-listed names (Saint-Gobain, Trelleborg, Nordson, Viscofan) [3][4][17]. Value creation is the mix shift from commodity toward regulated, high-tolerance medical — the playbook the ~$3.4B Zeus deal rewarded [18][19].

Outlook. The pipe two-thirds rides durable structural demand — aging-water replacement, lead-line rule spending, and plastic's steady share gain over metal — tempered by the housing cycle, resin normalization, and the unresolved DOJ probe [5][6][23]. The profile one-third rides medical demographics and reshoring at its high end while its commodity end waits on a construction recovery; its swing factor is chemical regulation — how hard the EPA lands on vinyl chloride, phthalates, and PFAS will decide which chemistries and margins survive [7][8][4]. Across the whole level, expect continued consolidation, with the premium accruing to whoever owns the regulated, high-barrier ends — large-diameter and engineered pipe on one side, cleanroom medical tubing on the other — and the commodity middle remaining a resin-cost-driven grind.

---

Sources

1. U.S. Census Bureau, 2022 Economic Census (receipts, firms, concentration ratios, HHI) and County Business Patterns 2023 (establishments, employment, payroll), NAICS 32612 and child industries 326121 and 326122 (our ground-truth ingested figures), 2022–2023. https://data.census.gov/
2. U.S. Census Bureau, 2022 Economic Census — Concentration Ratios / Industry Statistics, NAICS 326122; IBISWorld / NAICS.com, "NAICS Code 326122" (definition, exclusions, import note), 2022–2024. https://www.naics.com/naics-code-description/?code=326122
3. U.S. Census Bureau, 2022 Economic Census, NAICS 326121; NAICS Association, "NAICS Code 326121 — Unlaminated Plastics Profile Shape Manufacturing" (definition, exclusions, concentration), 2022. https://www.naics.com/naics-code-description/?v=2022&code=326121
4. MarketsandMarkets, "Fluoropolymer Tubing Market worth $813.5 million by 2030" and "Medical Plastics Tubing Market — Leading Players" (Saint-Gobain, Nordson, Trelleborg, Freudenberg Medical, W.L. Gore; PFAS note), 2025. https://www.prnewswire.com/news-releases/fluoropolymer-tubing-market-worth-813-5-million-by-2030---exclusive-report-by-marketsandmarkets-302568018.html
5. U.S. EPA, Final Lead and Copper Rule Improvements and IIJA lead-service-line funding, 2024. https://www.epa.gov/newsreleases/biden-harris-administration-issues-final-rule-requiring-replacement-lead-pipes-within
6. Saveri Law Firm / The D&O Diary, PVC Pipes Price-Fixing Litigation; DOJ antitrust subpoena; OPIS settlement ($3M), 2024–2025. https://www.saverilawfirm.com/our-cases/pvc-pipes-price-fixing-litigation
7. U.S. EPA, Risk Evaluation for Vinyl Chloride (TSCA High-Priority designation Dec 2024; draft scope Jan 2025), 2024–2025. https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-evaluation-vinyl-chloride
8. U.S. EPA, Risk Evaluation for Diethylhexyl Phthalate (DEHP) and phthalates schedule (DEHP evaluation Dec 2025), 2024–2025. https://www.epa.gov/chemicals-under-tsca/epa-announces-schedule-tsca-risk-evaluations-phthalates
9. Advanced Drainage Systems, Fourth Quarter and Fiscal Year 2025 Results; ADS recycling scale, 2021–2025. https://www.businesswire.com/news/home/20250515034000/en/Advanced-Drainage-Systems-Announces-Fourth-Quarter-and-Fiscal-Year-2025-Results
10. Advanced Drainage Systems, Form 10-K FY2026 ($3.05B net sales; margins; customer concentration; recycling), 2026. https://www.sec.gov/Archives/edgar/data/1604028/000160402826000019/wms-20260331.htm
11. Atkore Inc., FY2024 Investor Presentation / Form 8-K (segment mix; conduit classification note), 2024. https://www.sec.gov/Archives/edgar/data/1666138/000166613824000172/atkrnov24ir.htm
12. Westlake Corporation, Fourth Quarter and Full Year 2024 Results (Housing & Infrastructure Products segment $4.3B), 2025. https://investors.westlake.com/news-releases/news-release-details/westlake-corporation-reports-fourth-quarter-and-full-year-2024
13. Westlake Corporation, Form 10-K FY2024 (Westlake Pipe & Fittings; PVCO investment; PVC antitrust disclosure), 2024–2025. https://www.sec.gov/Archives/edgar/data/1262823/000126282325000011/wlk-20241231.htm
14. Otter Tail Corporation, 2025 Annual Report / Form 10-K (Plastics segment $423M revenue; customer concentration; resin supply; margin normalization), 2026. https://www.sec.gov/Archives/edgar/data/1466593/000146659326000008/ottr-20251231.htm
15. Wikipedia, "JM Eagle," 2024. https://en.wikipedia.org/wiki/JM_Eagle
16. Plastics News, "Infrastructure projects ramp up, but plastic pipe producers face more scrutiny" (major U.S. suppliers), 2024. https://www.plasticsnews.com/news/infrastructure-projects-ramp-plastic-pipe-producers-face-more-scrutiny
17. Wikipedia, "Viscofan" (global sausage-casing leader; plastic casings a subset), 2025. https://en.wikipedia.org/wiki/Viscofan
18. PR Newswire / EQT, "EQT Private Equity to acquire Zeus, a global leader in advanced polymer components" (~$3.4B, ~17x revenue), 2023. https://www.prnewswire.com/news-releases/eqt-private-equity-to-acquire-zeus-a-global-leader-in-advanced-polymer-components-used-in-life-saving-medical-procedures-302017955.html
19. SC Biz News, "Orangeburg medical device manufacturer Zeus acquired in $3B deal," 2023. https://scbiz.com/orangeburg-based-medical-device-manufacturer-zeus-acquired-in-3b-deal/
20. Plastics News, "Report: Private equity firm buying Tekni-Plex for $1.5 billion" (Genstar Capital), 2017. https://www.plasticsnews.com/article/20170904/NEWS/170909978/report-private-equity-firm-buying-tekni-plex-for-1-5-billion
21. Business Wire, "Pexco LLC Acquires Plastic Profiles" (Odyssey Investment Partners ownership), 2022. https://www.businesswire.com/news/home/20221102006036/en/Pexco-LLC-Acquires-Plastic-Profiles
22. Quanex Building Products, Form 10-K FY2025 ($1.84B sales; adjacent rigid-vinyl fenestration; different NAICS code), 2025. https://www.sec.gov/Archives/edgar/data/1423221/000142322125000100/nx-20251031.htm
23. Plastics Technology, "December 2025: Lower Prices for PE, PP, PS and PVC; PET Higher," 2025. https://www.ptonline.com/articles/december-2025-lower-prices-for-pe-pp-ps-and-pvc-pet-higher
24. S&P Global, "Commodities 2026: Global 2026 PVC on the edge of production cuts and trade flow twists" (Westlake PVC plant shutdown Dec 2025), 2025. https://www.spglobal.com/energy/en/news-research/latest-news/chemicals/122325-commodities-2026-global-2026-pvc-on-the-edge-of-production-cuts-and-trade-flow-twists
25. U.S. Census Bureau, "New Residential Construction" (housing starts May 2026: 1.177M SAAR, −8.7% YoY), 2026. https://www.census.gov/construction/nrc/current/
26. U.S. EPA, Drinking Water Infrastructure Needs Survey and Assessment (7th report) ($625B over 20 years), 2023. https://www.epa.gov/dwsrf/epas-7th-drinking-water-infrastructure-needs-survey-and-assessment
27. U.S. EPA, Clean Watersheds Needs Survey ($630.1B 20-year need), 2022. https://www.epa.gov/cwns
28. NSF, Plastic Piping System Components Certification — NSF/ANSI 14 and NSF/ANSI/CAN 61; plumbing-code requirements, 2024–2025. https://www.nsf.org/water-systems/plastic-piping-system-components
29. U.S. EPA, Build America, Buy America (BABA) Overview (includes plastic/polymer products), 2023. https://www.epa.gov/baba/build-america-buy-america-baba-overview
30. Westlake Corporation, First Quarter 2026 Results ($67M charge to settle PVC price-fixing litigation), 2026. https://investors.westlake.com/news-releases/news-release-details/westlake-corporation-reports-first-quarter-2026-results
31. Aliaxis / IPEX, Aliaxis acquires Valencia Pipe Company division; acquires Johnson Controls CPVC business, 2023–2024. https://ipexna.com/news-and-events/press-releases/aliaxis-expands-in-the-western-united-states-by-acquiring-valencia-pipe-companys-pipe-fittings-manufacturing-division/
32. Georg Fischer, Final result of GF's voluntary recommended public cash tender offer for Uponor, 2023. https://www.gfps.com/int/en/about-us/media-center/news-details.html/news/gf/2023/final-result-of-gfs-voluntary-recommended-public-cash-tender-offer